Inflammatory Ocular Conditions Treatment

Topical Corticosteroid Therapy

The American College of Rheumatology conditionally recommends prednisolone acetate 1% topical drops over difluprednate for active chronic anterior uveitis (CAU) in children and adolescents with juvenile idiopathic arthritis 1, 2, 3, 4
Prednisolone acetate 1% remains the gold standard topical corticosteroid for ocular inflammation due to superior corneal penetration and extensive clinical experience 1, 2
Start with prednisolone acetate 1% at frequent dosing (every 1-2 hours while awake) for acute severe inflammation, then taper based on clinical response 2
For moderate inflammation, begin with 4-6 times daily dosing 1, 2
Monitor intraocular pressure (IOP) and anterior chamber inflammation at each visit, as topical glucocorticoid use at ≥2 drops/day significantly increases risk of IOP elevation 5

Loteprednol 0.5% suspension or gel is recommended as first-line for neuropathic corneal pain or conditions requiring prolonged anti-inflammatory therapy due to lower rates of IOP elevation and cataract formation 6, 7
Loteprednol demonstrates only 0.8% incidence of clinically significant IOP elevation (≥10 mmHg) with short-term use and 1.5% with long-term use 6, 7
The gel formulation contains significantly lower concentrations of the neurotoxic preservative benzalkonium chloride (0.003% vs 0.05-0.01% in other corticosteroids) 6, 7

Monitor within 1 month after each change in topical glucocorticoid dosing 1, 3, 4
For patients on stable topical therapy, examine no less frequently than every 3 months 1, 3, 4
Check IOP at every visit, as elevated IOP is the most common complication of topical corticosteroid therapy 5

Never use topical corticosteroids alone for posterior uveitis or retinal vasculitis—these conditions require systemic immunosuppression with azathioprine and corticosteroids 8
Avoid prolonged monotherapy with topical steroids beyond 3 months if requiring ≥1-2 drops daily, as this increases risk of steroid-induced complications without addressing underlying inflammation 2, 5
In patients with severe hyperalgesia or preservative intolerance, use preservative-free formulations such as compounded methylprednisolone 1% rather than standard preserved preparations 6, 7
Do not abruptly discontinue topical corticosteroids after prolonged use—taper slowly to prevent rebound inflammation 6